Organised by LSP (Life Sciences Partners) and Fortis companies, BioCapital Europe is now in its 6th successful consecutive year and has established itself as a platform allowing the most promising and emerging biotech companies from the Benelux as well as a selection of quality biotech companies from other European countries to present to an audience of dedicated biotech VCs. and institutional investors.

BioCapital Europe has become a showcase for the industry's progress in these regions, attracting over 100 high quality delegates.

The conference will be held on 5th March 2008.  VCs and Institutional Investors are invited to attend free of charge to this year's event

LSP (Life Sciences Partners) is a leading independent European venture capital firm, providing private equity financing to early- to mid-stage life-science companies. Since the late 1980s, LSP's management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry.

For example, LSP was a founding investor in Crucell, DNage, Qiagen, Rhein Biotech and Pharming. With EUR 400 million under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe's largest and most experienced specialist life-science investors. For more information about the LSP Group, please visit the website at www.lspvc.com.

Fortis is an international provider of banking and insurance services to personal, business and institutional customers. Fortis delivers a total package of financial products and services through its high-performance channels, and via intermediaries and other partners. Fortis ranks among Europe's top 20 financial institutions, with a market capitalisation of EUR43 billion. With excellent solvency, a presence in over 50 countries and a dedicated, professional workforce of 60,000, Fortis combines global strength with local flexibility. Fortis offers a full range of investment banking services including private placements, public equity offerings and mergers & acquisitions. Within biotechnology, Fortis has created a research driven, global approach to its investment banking and brokerage activities. Fortis' dedicated biotech team operates from Amsterdam, Frankfurt, Brussels, New York and Boston. As one of the oldest European merchant banks, Fortis values the tradition of building long-term, personalized relationships with its clients at each stage of their growth. Please visit the Fortis Merchant Banking website at www.merchantbanking.fortis.com for more information.

Click here to register for the event